R. L. Albin, A. B. Young, and J. B. Penney, The functional anatomy of basal ganglia disorders, Trends Neurosci, vol.12, issue.10, pp.366-75, 1989.

G. E. Alexander, M. D. Crutcher, and M. R. Delong, Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions, Prog Brain Res, vol.85, pp.119-165, 1990.

E. Altschuler, Gastric Helicobacter pylori infection as a cause of idiopathic Parkinson disease and non-arteric anterior optic ischemic neuropathy, Med Hypotheses, vol.47, issue.5, pp.413-417, 1996.

L. Alvarez-arellano and C. Maldonado-bernal, Helicobacter pylori and neurological diseases: Married by the laws of inflammation, World J Gastrointest Pathophysiol, vol.5, issue.4, pp.400-404, 2014.

P. G. Ambrose, S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo et al., Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.44, issue.1, pp.79-86, 2007.

G. Arru, E. Caggiu, K. Paulus, G. P. Sechi, G. Mameli et al., Is there a role for Mycobacterium avium subspecies paratuberculosis in Parkinson's disease?, J Neuroimmunol, vol.293, pp.86-90, 2016.

P. K. Auluck, M. C. Meulener, and N. M. Bonini, Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila, J Biol Chem, vol.280, issue.4, pp.2873-2881, 2005.

E. L. Beatman, A. Massey, K. D. Shives, K. S. Burrack, M. Chamanian et al., Alpha-Synuclein Expression Restricts RNA Viral Infections in the Brain, J Virol, 2015.

J. R. Berger and G. Arendt, HIV dementia: the role of the basal ganglia and dopaminergic systems, J Psychopharmacol, vol.14, issue.3, pp.214-235, 2000.

S. Bido, M. Marti, and M. Morari, Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels, J Neurochem, vol.118, issue.6, pp.1043-55, 2011.

W. Bi, L. Zhu, X. Jing, Z. Zeng, Y. Liang et al., Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway, Mol Med Rep, vol.10, issue.4, pp.179-188, 2014.

W. Bi, L. Zhu, C. Wang, Y. Liang, J. Liu et al., Rifampicin inhibits microglial inflammation and improves neuron survival against inflammation, Brain Res, vol.1395, pp.12-20, 2011.

R. Bisht, B. Kaur, H. Gupta, and A. Prakash, Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats, Neurotoxicology, vol.44, pp.71-80, 2014.

A. B. Blázquez, M. A. Martín-acebes, and J. C. Saiz, Inhibition of West Nile Virus Multiplication in Cell Culture by Anti-Parkinsonian Drugs, Front Microbiol, vol.7, p.296, 2016.

D. Blum, A. Chtarto, L. Tenenbaum, J. Brotchi, and M. Levivier, Clinical potential of minocycline for neurodegenerative disorders, Neurobiol Dis, vol.17, issue.3, pp.359-66, 2004.

J. Braham, Adjuvants to L-dopa for Parkinsonism, Br Med J, vol.2, issue.5708, p.540, 1970.

V. Braniste, M. Al-asmakh, C. Kowal, F. Anuar, A. Abbaspour et al., The gut microbiota influences blood-brain barrier permeability in mice, Sci Transl Med, vol.6, issue.263, pp.263-158, 2014.

X. L. Bu, X. Wang, Y. Xiang, L. L. Shen, Q. H. Wang et al., The association between infectious burden and Parkinson's disease: A case-control study, Parkinsonism Relat Disord, vol.21, issue.8, pp.877-81, 2015.

C. Buddhala, S. K. Loftin, B. M. Kuley, N. J. Cairns, M. C. Campbell et al., Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease, Ann Clin Transl Neurol, vol.2, issue.10, pp.949-59, 2015.

G. Çamc? and S. O?uz, Association between Parkinson's Disease and Helicobacter Pylori, J Clin Neurol, vol.12, issue.2, pp.147-50, 2016.

C. C. Cardoso, A. C. Pereira, C. De-sales-marques, and M. O. Moraes, Leprosy susceptibility: genetic variations regulate innate and adaptive immunity, and disease outcome, Future Microbiol, vol.6, issue.5, pp.533-582, 2011.

M. G. Cersósimo, M. C. Scorticati, and F. E. Micheli, Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease

, Medicina (B Aires), vol.60, issue.3, pp.321-326, 2000.

L. Chen and W. H. Yung, GABAergic neurotransmission in globus pallidus and its involvement in neurologic disorders, Sheng Li Xue Bao, vol.56, issue.4, pp.427-462, 2004.

H. Chen, O. Reilly, E. J. Schwarzschild, M. A. Ascherio, and A. , Peripheral inflammatory biomarkers and risk of Parkinson's disease, Am J Epidemiol, vol.167, pp.90-95, 2007.

H. Chen, E. Jacobs, M. A. Schwarzschild, M. L. Mccullough, E. E. Calle et al., Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease, Ann Neurol, vol.58, pp.963-67, 2005.

Y. Cho, H. J. Son, E. M. Kim, J. H. Choi, S. T. Kim et al., Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3, Neurotox Res, vol.16, issue.4, pp.361-71, 2009.

T. Chotibut, R. W. Davis, J. C. Arnold, Z. Frenchek, S. Gurwara et al., Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model, Mol Neurobiol, vol.49, issue.3, pp.1282-92, 2014.

I. K. Chun, Y. H. Lee, K. E. Lee, and H. S. Gwak, Design and evaluation of levodopa methyl ester intranasal delivery systems, J Parkinsons Dis, vol.1, issue.1, pp.101-108, 2011.

M. R. Cookson, The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease, Nat Rev Neurosci, vol.11, issue.12, pp.791-798, 2010.

W. C. Davis, On deaf ears, Mycobacterium avium paratuberculosis in pathogenesis Crohn's and other diseases, World J Gastroenterol, vol.21, issue.48, pp.13411-13418, 2015.

M. Delong and T. Wichmann, Changing views of basal ganglia circuits and circuit disorders, Clin EEG Neurosci, vol.41, issue.2, pp.61-68, 2010.

A. Destee, Les stratégies du traitement antiparkinsonien, Rev Prat, vol.55, issue.7, pp.723-731, 2005.

A. Dixit, G. Srivastava, D. Verma, M. Mishra, P. K. Singh et al., Minocycline, levodopa and MnTMPyP induced changes in the mitochondrial proteome profile of MPTP and maneb and paraquat mice models of Parkinson's disease, Biochim Biophys Acta, 2013.

S. M. Dobbs, R. J. Dobbs, C. Weller, A. Charlett, A. A. Taylor et al., Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota, J Neurovirol, vol.22, issue.1, pp.22-32, 2016.

C. M. Dow, paratuberculosis and Parkinson's disease-is this a trigger, Med Hypotheses, vol.83, issue.6, pp.709-721, 2014.

C. Duyckaerts, V. Sazdovitch, and D. Seilhean, Évolution des connaissances sur le processus pathologique de la maladie de Parkinson, Bull. Acad. Natle Méd, vol.194, issue.7, pp.1287-1304, 2010.

F. Fang, K. Wirdefeldt, A. Jacks, F. Kamel, W. Ye et al., CNS infections, sepsis and risk of Parkinson's disease, Int J Epidemiol, vol.41, issue.4, pp.1042-1051, 2012.

A. Fasano, N. P. Visanji, L. W. Liu, A. E. Lang, and R. F. Pfeiffer, Gastrointestinal dysfunction in Parkinson's disease, Lancet Neurol, vol.14, issue.6, pp.625-664, 2015.

E. Fazzini, J. Fleming, and S. Fahn, Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease, Mov Disord, vol.7, issue.2, pp.153-161, 1992.

H. H. Fernandez, Update on Parkinson disease, Cleve Clin J Med, vol.82, issue.9, pp.563-571, 2015.

G. Fiorini, J. M. Bland, E. Hughes, V. Castelli, and D. Vaira, A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy, J Gastrointestin Liver Dis, vol.24, issue.1, pp.95-100, 2015.

X. Gao, H. Chen, M. A. Schwarzschild, and A. Ascherio, Use of ibuprofen and risk of Parkinson disease, Neurology, vol.76, pp.863-69, 2011.

T. Gasser, Genetics of Parkinson's disease, Dialogues Clin Neurosci, vol.6, issue.3, pp.295-301, 2004.

O. S. Gershanik, M. R. Luquin, O. Scipioni, and J. A. Obeso, Isoniazid therapy in Parkinson's disease, Mov Disord, vol.3, issue.2, pp.133-142, 1988.

C. G. Goetz and G. T. Stebbins, Mortality and hallucinations in nursing home patients with advanced Parkinson's disease, Neurology, vol.45, pp.669-671, 1995.

M. T. Gray, D. G. Munoz, M. G. Schlossmacher, D. A. Gray, and J. M. Woulfe, Protective effect of vagotomy suggests source organ for Parkinson disease, Ann Neurol, vol.78, issue.5, pp.834-839, 2015.

T. Gumbo, A. Louie, W. Liu, D. Brown, P. G. Ambrose et al., Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations, Antimicrob Agents Chemother, 2007.

M. A. Harris, J. K. Tsui, S. A. Marion, H. Shen, and K. Teschke, Association of Parkinson's disease with infections and occupational exposure to possible vectors, Mov Disord, vol.27, issue.9, pp.1111-1118, 2012.

H. Hashim, S. Azmin, H. Razlan, N. W. Yahya, H. J. Tan et al., Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease, PLoS One, vol.9, issue.11, p.112330, 2014.

S. C. Ho, C. C. Hsu, C. R. Pawlak, M. A. Tikhonova, T. J. Lai et al., Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model, Behav Brain Res, vol.268, pp.177-84, 2014.

H. Hong, B. S. Kim, and H. I. Im, Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric Disorders, Int Neurourol J, vol.20, issue.1, pp.2-7, 2016.

G. Hubsher, M. Haider, and M. S. Okun, Amantadine: the journey from fighting flu to treating Parkinson disease, Neurology, vol.78, issue.14, pp.1096-1105, 2012.

C. Y. Hsu, C. S. Hung, H. M. Chang, W. C. Liao, S. C. Ho et al., Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia, Neuropharmacology, vol.91, pp.43-56, 2015.

I. U. Isaias, J. Spiegel, J. Brumberg, K. P. Cosgrove, G. Marotta et al., Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease, Front Aging Neurosci, vol.6, p.213, 2014.

H. Jang, D. Boltz, K. Sturm-ramirez, K. R. Shepherd, Y. Jiao et al., Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration, Proc Natl Acad Sci U S A, vol.106, issue.33, pp.14063-14071, 2009.

H. Jang, D. A. Boltz, and R. G. Webster, Smeyne RJ. (b) Viral parkinsonism, Biochim Biophys Acta, vol.1792, issue.7, pp.714-735, 2009.

J. Jiang, J. Jiang, Y. Zuo, and Z. Gu, Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson's disease, Int J Mol Med, vol.31, issue.4, pp.825-857, 2013.

A. Kapurniotu, Targeting alpha-synuclein in Parkinson's disease, Chem Biol, 2004.

H. Kaufmann, Cutting the vagal highway blocks one point of entry for prion-like alphasynuclein, Ann Neurol, vol.78, issue.4, pp.520-521, 2015.

U. Kilic, E. Kilic, P. Lingor, B. Yulug, and M. Bähr, Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro, Acta Neuropathol, vol.108, issue.1, pp.65-73, 2004.

J. S. Kim, I. S. Choi, and M. C. Lee, Reversible parkinsonism and dystonia following probable mycoplasma pneumoniae infection, Mov Disord, vol.10, issue.4, pp.510-512, 1995.

G. H. Kim, J. E. Kim, S. J. Rhie, and S. Yoon, The Role of Oxidative Stress in Neurodegenerative Diseases, Exp Neurobiol, vol.24, issue.4, pp.325-365, 2015.

S. Kohbata and K. Shimokawa, Circulating antibody to Nocardia in the serum of patients with Parkinson's disease, Adv Neurol, vol.60, pp.355-362, 1993.

G. La?an, H. Dang, B. Middleton, M. A. Horwitz, J. Tian et al., Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease, J Neurosci Res, vol.91, issue.10, pp.1292-302, 2013.

E. Lahner, B. Annibale, D. Fave, and G. , Systematic review: Helicobacter pylori infection and impaired drug absorption, Aliment Pharmacol Ther, vol.29, issue.4, pp.379-86, 2009.

E. Lahner, C. Virili, M. G. Santaguida, B. Annibale, and M. Centanni, Helicobacter pylori infection and drugs malabsorption, World J Gastroenterol, vol.20, issue.30, pp.10331-10338, 2014.

J. L. Lanciego, N. Luquin, and J. A. Obeso, Functional Neuroanatomy of the Basal Ganglia, Cold Spring Harb Perspect Med, vol.2, issue.12, p.9621, 2012.

M. Lazzarini, S. Martin, M. Mitkovski, R. R. Vozari, W. Stühmer et al., Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model, Glia, vol.61, issue.7, pp.1084-100, 2013.

T. C. Leung, C. N. Lui, L. W. Chen, W. H. Yung, Y. S. Chan et al., Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats, ACS Chem Neurosci, vol.3, issue.1, pp.22-30, 2012.

H. Leung and V. Mok, Parkinson's disease: aetiology, diagnosis, and management, Hong Kong Med J, vol.11, issue.6, pp.476-89, 2005.

J. Li, M. Zhu, S. Rajamani, V. N. Uversky, and A. L. Fink, Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils, Chem Biol, vol.11, issue.11, pp.1513-1534, 2004.

D. Limongi and S. Baldelli, Redox Imbalance and Viral Infections in Neurodegenerative Diseases, Oxid Med Cell Longev, p.6547248, 2016.

I. Litvan, G. Halliday, M. Hallett, C. G. Goetz, W. Rocca et al., The etiopathogenesis of Parkinson disease and suggestions for future research. Part I, J Neuropathol Exp Neurol, vol.66, issue.4, pp.251-258, 2007.

G. Liu, L. Aliaga, and H. Cai, ?-synuclein, LRRK2 and their interplay in Parkinson's disease, Future Neurol, vol.7, issue.2, pp.145-153, 2012.

B. Liu, H. Chen, F. Fang, A. Tillander, and K. Wirdefeldt, Early-Life Factors and Risk of Parkinson's Disease: A Register-Based Cohort Study, PLoS One, vol.11, issue.4, p.152841, 2016.

B. Liu, H. M. Gao, and J. S. Hong, Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation, Environ Health Perspect, vol.111, issue.8, pp.1065-73, 2003.

L. Ma, L. Wei, F. Wu, Z. Hu, Z. Liu et al., Advances with microRNAs in Parkinson's disease research, Drug Des Devel Ther, vol.7, pp.1103-1116, 2013.

V. Machado, T. Zöller, A. Attaai, and B. Spittau, Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's DiseaseLessons from Transgenic Mice, Int J Mol Sci, vol.17, issue.2, p.151, 2016.

B. S. Main, M. Zhang, K. M. Brody, S. Ayton, T. Frugier et al., Type-1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease, Glia, vol.64, issue.9, pp.1590-604, 2016.

C. Malagelada, E. J. Ryu, S. C. Biswas, J. , V. Greene et al., RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation, J Neurosci, vol.26, issue.39, pp.9996-10005, 2006.

C. Malagelada, Z. H. Jin, J. , V. Przedborski, S. Greene et al., Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease, J Neurosci, vol.30, issue.3, pp.1166-75, 2010.

P. S. Manzanillo, J. S. Ayres, R. O. Watson, A. C. Collins, G. Souza et al., The ubiquitin ligase parkin mediates resistance to intracellular pathogens, Nature, vol.501, issue.7468, pp.512-518, 2013.

C. Mattock, M. Marmot, and G. Stern, Could Parkinson's disease follow intra-uterine influenza?: a speculative hypothesis, J Neurol Neurosurg Psychiatry, vol.51, issue.6, pp.753-759, 1988.

O. Miman, O. Y. Kusbeci, O. C. Aktepe, and Z. Cetinkaya, The probable relation between Toxoplasma gondii and Parkinson's disease, Neurosci Lett, vol.475, issue.3, pp.129-160, 2010.

S. M. Mirsattari, C. Power, and A. Nath, Parkinsonism with HIV infection, Mov Disord, 1998.

A. Mulak and B. Bonaz, Brain-gut-microbiota axis in Parkinson's disease, World J Gastroenterol, vol.21, issue.37, pp.10609-10629, 2015.

G. Natale, L. Pasquali, A. Paparelli, and F. Fornai, Parallel manifestations of neuropathologies in the enteric and central nervous systems, Neurogastroenterol Motil, vol.23, issue.12, pp.1056-65, 2011.

H. H. Nielsen, J. Qiu, S. Friis, L. Wermuth, and B. Ritz, Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark, Eur J Neurol, vol.19, issue.6, pp.864-873, 2012.

N. Investigators, A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease, Neurology, vol.66, issue.5, pp.664-71, 2006.

N. Investigators, A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results, Clin Neuropharmacol, vol.31, issue.3, pp.141-50, 2008.

S. Noël, M. P. Guillaume, N. Telerman-toppet, and E. Cogan, Movement disorders due to cerebral Toxoplasma gondii infection in patients with the acquired immunodeficiency syndrome (AIDS)

, Acta Neurol Belg, vol.92, issue.3, pp.148-56, 1992.

A. Ogata, K. Tashiro, S. Nukuzuma, K. Nagashima, and W. W. Hall, A rat model of Parkinson's disease induced by Japanese encephalitis virus, J Neurovirol, vol.3, issue.2, pp.141-148, 1997.

Y. Oida, K. Kitaichi, H. Nakayama, Y. Ito, Y. Fujimoto et al., Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain, Brain Res, 2006.
DOI : 10.1016/j.brainres.2006.01.116

C. Paci, A. Thomas, and M. Onofrj, Amantadine for dyskinesia in patients affected by severe Parkinson's disease, Neurol Sci, vol.22, issue.1, pp.75-81, 2001.
DOI : 10.1007/s100720170054

G. M. Pacifici, M. Nardini, P. Ferrari, R. Latini, C. Fieschi et al., Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect, Br J Clin Pharmacol, vol.3, issue.5, pp.883-892, 1976.

R. Pahwa, C. M. Tanner, R. A. Hauser, K. Sethi, S. Isaacson et al., Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study), Mov Disord, vol.30, issue.6, pp.788-95, 2015.

T. Pan, S. Kondo, W. Zhu, W. Xie, J. Jankovic et al., Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement, Neurobiol Dis, 2008.

T. Pan, P. Rawal, Y. Wu, W. Xie, J. Jankovic et al., Rapamycin protects against rotenoneinduced apoptosis through autophagy induction, Neuroscience, vol.164, issue.2, pp.541-51, 2009.
DOI : 10.1016/j.neuroscience.2009.08.014

J. Parkinson, An essay on the shaking palsy 1817, J Neuropsychiatry Clin Neurosci, vol.14, issue.2, pp.223-259, 2002.

J. Pasipanodya and T. Gumbo, An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future, Antimicrob Agents Chemother, vol.55, issue.1, pp.24-34, 2011.
DOI : 10.1128/aac.00749-10

URL : https://aac.asm.org/content/55/1/24.full.pdf

M. W. Pellegrino and C. M. Haynes, Mitophagy and the mitochondrial unfolded protein response in neurodegeneration and bacterial infection, BMC Biol, vol.13, p.22, 2015.

M. Pierantozzi, A. Pietroiusti, G. Sancesario, G. Lunardi, E. Fedele et al., Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients, Neurol Sci, vol.22, issue.1, pp.89-91, 2001.
DOI : 10.1007/s100720170061

C. Poivert, J. P. Graftieaux, P. Gomis, B. Scherpereel, and J. M. Malinovsky, Transcient improvement of extrapyramidal syndrome after general anaesthesia, Ann Fr Anesth Reanim, vol.31, issue.3, pp.251-255, 2012.

R. B. Postuma, Can Parkinson's Disease Come From the Gut?, Mov Disord, vol.30, issue.10, p.1325, 2015.

R. Premaratna, S. H. Wijayalath, J. K. Miththinda, N. K. Bandara, and H. J. Silva, Scrub typhus mimicking Parkinson's disease, BMC Res Notes, vol.8, p.438, 2015.
DOI : 10.1186/s13104-015-1428-x

URL : https://bmcresnotes.biomedcentral.com/track/pdf/10.1186/s13104-015-1428-x

L. Qin, X. Wu, M. L. Block, Y. Liu, G. R. Breese et al., Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration, Glia, vol.55, pp.453-62, 2007.
DOI : 10.1002/glia.20467

URL : http://europepmc.org/articles/pmc2871685?pdf=render

C. R. Rainier-pope, Treatment with diazepam of children with drug-induced extrapyramidal symptoms, S Afr Med J, vol.55, issue.9, pp.328-358, 1979.

C. Rangel-barajas, I. Coronel, and B. Florán, Dopamine Receptors and Neurodegeneration, Aging Dis, vol.6, issue.5, pp.349-68, 2015.
DOI : 10.14336/ad.2015.0330

URL : http://www.aginganddisease.org/EN/article/downloadArticleFile.do?attachType=PDF&id=147472

J. Ren, C. Shen, and C. G. , A rare case of tuberculosis with motor neuron disease, World J Surg Oncol, vol.12, p.381, 2014.

A. D. Reynolds, J. G. Glanzer, I. Kadiu, M. Ricardo-dukelow, A. Chaudhuri et al., Nitrated alphasynucleinactivated microglial profiling for Parkinson's disease, Journal of Neurochemistry, vol.104, issue.6, pp.1504-1525, 2008.
DOI : 10.1111/j.1471-4159.2007.05087.x

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1471-4159.2007.05087.x

F. Richy and F. Mégraud, Helicobacter pylori infection as a cause of extra-digestive diseases: myth or reality?, Gastroenterol Clin Biol, vol.27, issue.3, pp.459-66, 2003.

N. P. Rocha, A. S. Miranda, and A. L. Teixeira, Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies, Biomed Res Int, p.628192, 2015.

T. T. Rohn and L. W. Catlin, Immunolocalization of influenza A virus and markers of inflammation in the human Parkinson's disease brain, PLoS One, vol.6, issue.5, p.20495, 2011.

J. D. Rothstein, S. Patel, M. R. Regan, C. Haenggeli, Y. H. Huang et al., Betalactam antibiotics offer neuroprotection by increasing glutamate transporter expression, Nature, vol.433, issue.7021, pp.73-80, 2005.

P. Ruzza, G. Siligardi, R. Hussain, A. Marchiani, M. Islami et al., Ceftriaxone blocks the polymerization of ?-synuclein and exerts neuroprotective effects in vitro, ACS Chem Neurosci, vol.5, issue.1, pp.30-38, 2014.

E. T. Sakowski, S. Koster, P. Celhay, C. Park, H. S. Shrestha et al., Ubiquilin 1 Promotes IFN-?-Induced Xenophagy of Mycobacterium tuberculosis, PLoS Pathog, vol.11, issue.7, p.1005076, 2015.

M. E. Sauer, H. Salomão, G. B. Ramos, D. Espindula, H. R. Rodrigues et al., Genetics of leprosy: expected and unexpected developments and perspectives, Clin Dermatol, vol.33, issue.1, pp.99-107, 2015.

H. Sawada, T. Oeda, S. Kuno, M. Nomoto, K. Yamamoto et al.,

A. Study-group, Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial, PLoS One, vol.5, issue.12, p.15298, 2010.

J. Segura-aguilar, P. I. Muñoz, P. Ferrari, E. Zecca, L. Zucca et al., Protective and toxic roles of dopamine in Parkinson's disease, J Neurochem, vol.129, issue.6, pp.898-915, 2014.

A. Sekigawa, Y. Takamatsu, K. Sekiyama, and M. Hashimoto, Role of ?-and ?-Synucleins in the Axonal Pathology of Parkinson's Disease and Related Synucleinopathies, Biomolecules, 2015.

N. Sheehan and . La-maladie-de-parkinson, Pharmactuel, vol.33, issue.2, pp.67-74, 2000.

C. H. Shen, C. H. Chou, F. C. Liu, T. Y. Lin, W. Y. Huang et al., Association Between Tuberculosis and Parkinson Disease: A Nationwide, Population-Based Cohort Study, Medicine (Baltimore), vol.95, issue.8, p.2883, 2016.

H. Sjölinder and A. B. Jonsson, Olfactory nerve-a novel invasion route of Neisseria meningitidis to reach the meninges, PLoS One, vol.5, issue.11, p.14034, 2010.

P. Sokoloff, M. P. Martres, and J. C. Schwartz, La famille des récepteurs de la dopamine, médecine/sciences, vol.1, issue.9, pp.12-20, 1993.

E. Svensson, E. Horváth-puhó, R. W. Thomsen, J. C. Djurhuus, L. Pedersen et al., Vagotomy and subsequent risk of Parkinson's disease, Ann Neurol, 2015.

M. Takahashi, T. Yamada, S. Nakajima, K. Nakajima, T. Yamamoto et al., The substantia nigra is a major target for neurovirulent influenza A virus, J Exp Med, vol.181, issue.6, pp.2161-2170, 1995.

M. Takahashi and T. Yamada, Viral etiology for Parkinson's disease-a possible role of influenza A virus infection, Jpn J Infect Dis, vol.52, issue.3, pp.89-98, 1999.

A. H. Tan, S. Mahadeva, C. Marras, A. M. Thalha, C. K. Kiew et al., Helicobacter pylori infection is associated with worse severity of Parkinson's disease, Parkinsonism Relat Disord, vol.21, issue.3, pp.221-226, 2015.

A. Tarutani, G. Suzuki, A. Shimozawa, T. Nonaka, H. Akiyama et al., Effect of Fragmented Pathogenic ?-Synuclein Seeds on Prion-like Propagation, J Biol Chem, vol.291, issue.36, pp.18675-88, 2016.

D. Thibault, C. Kortleven, C. Fasano, D. Bo, G. Trudeau et al., Recent discoveries on the function and plasticity of central dopamine pathways, Med Sci, vol.26, issue.2, pp.165-70, 2010.

A. Thomas, D. Iacono, A. L. Luciano, K. Armellino, D. Iorio et al., Duration of amantadine benefit on dyskinesia of severe Parkinson's disease, J Neurol Neurosurg Psychiatry, vol.75, issue.1, pp.141-144, 2004.

M. Thomas and W. D. Le, Minocycline: neuroprotective mechanisms in Parkinson's disease, Curr Pharm Des, vol.10, issue.b, pp.679-86, 2004.

T. Tomiyama, S. Asano, Y. Suwa, T. Morita, K. Kataoka et al., Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro, Biochem Biophys Res Commun, vol.204, issue.1, pp.76-83, 1994.

T. Tomiyama, A. Shoji, K. Kataoka, Y. Suwa, S. Asano et al., Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger, J Biol Chem, vol.271, issue.12, pp.6839-6883, 1996.

H. H. Tsai, H. H. Liou, C. H. Muo, C. Z. Lee, R. F. Yen et al., Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study, Neurology, vol.86, issue.9, pp.840-846, 2016.

K. Ubhi, E. Rockenstein, M. Mante, C. Patrick, A. Adame et al., Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy, Neuroreport, vol.19, issue.13, pp.1271-1277, 2008.

T. Umeda, K. Ono, A. Sakai, M. Yamashita, M. Mizuguchi et al., Rifampicin is a candidate preventive medicine against amyloid-? and tau oligomers, Brain, vol.139, issue.5, pp.1568-86, 2016.

T. Wang and J. C. Hay, Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease, Front Neurosci, vol.9, p.433, 2015.

P. Q. Wang, S. G. Sun, and X. Qiao, Protective effects of doxycycline upon dopaminergic neuron in LPS-induced rat model of Parkinson's disease, Zhonghua Yi Xue Za Zhi, vol.89, p.1346, 2009.

K. J. Wangensteen, E. L. Krawitt, R. W. Hamill, and J. T. Boyd, Hepatitis C virus infection: a risk factor for Parkinson's disease, J Viral Hepat, vol.23, issue.7, p.535, 2016.

K. Weissenborn, J. C. Ennen, M. Bokemeyer, B. Ahl, U. Wurster et al., Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment, Gut, vol.55, issue.11, pp.1624-1654, 2006.

D. Weintraub, C. L. Comella, and S. Horn, Parkinson's disease-Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment, Am J Manag Care, vol.14, issue.2, pp.40-48, 2008.

G. K. Wenning, O. Connell, M. T. Patsalos, P. N. Quinn, and N. P. , A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease, Mov Disord, vol.10, issue.5, pp.664-671, 1995.

I. M. Westhovens, V. Abeele, M. E. Messiaen, P. E. Van-der-hilst, and . Jch, Systemic BCG infection in a patient with pancytopaenia and fever 9 years after intravesical BCG administration for bladder cancer, BMJ Case Rep, 2016.

P. S. Whitton, Inflammation as a causative factor in the aetiology of Parkinson's disease, Br J Pharmacol, vol.150, issue.8, pp.963-76, 2007.

D. W?odarek, W. Pakszys, and M. Barlik, Helicobacter pylori-does it only cause gastroduodenal disease?, Pol Merkur Lekarski, vol.11, issue.65, pp.456-465, 2001.

W. Y. Wu, K. H. Kang, S. L. Chen, S. Y. Chiu, A. M. Yen et al., Hepatitis C virus infection: a risk factor for Parkinson's disease, J Viral Hepat, vol.22, issue.10, pp.784-91, 2015.

M. Q. Xu, H. L. Cao, W. Q. Wang, S. Wang, X. C. Cao et al., Fecal microbiota transplantation broadening its application beyond intestinal disorders, World J Gastroenterol, vol.21, issue.1, pp.102-113, 2015.

J. Yang, F. Qi, and Z. Yao, Neonatal Bacillus Calmette-Guérin vaccination alleviates lipopolysaccharide-induced neurobehavioral impairments and neuroinflammation in adult mice, Mol Med Rep, vol.14, issue.2, pp.1574-86, 2016.

J. Yong, G. Lacan, H. Dang, T. Hsieh, B. Middleton et al., BCG vaccine-induced neuroprotection in a mouse model of Parkinson's disease, PLoS One, vol.6, issue.1, p.16610, 2011.

D. Zemke and A. Majid, The potential of minocycline for neuroprotection in human neurologic disease, Clin Neuropharmacol, vol.27, issue.6, pp.293-301, 2004.

L. Zhou, M. Miranda-saksena, and N. K. Saksena, Viruses and neurodegeneration, Synopsis des récepteurs dopaminergiques (d'après Sokoloff, vol.10, 1993.

. Barajas, Annexe 2 : Voies de signalisation intracellulaire des récepteurs dopaminergiques de la famille D1 (d'après Ranger, 2015.

. Barajas, Voies de signalisation intracellulaire des récepteurs dopaminergiques de la famille D2 (d'après Ranger, Annexe, vol.3, 2015.